Malignant breast tumors that belong to the HER2-enriched and TNBC molecular subtypes are often highly immunogenic, while malignant breast tumors that express ER and PR hormone receptors tend to have a medium to low level of immunogenicity. This evidence concerns the gene PGR and breast cancer.